DNA vs ANNX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DNA · Ginkgo Bioworks$11.29 ▲ 13.35%
ANNX · Annexon$4.20 ▲ 4.87%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DNA +28.7%
- ANNX +40.9%
Head to head
| Metric | DNA | ANNX |
|---|---|---|
| Price | $11.29 | $4.20 |
| Change today | ▲ 13.35% | ▲ 4.87% |
| Market cap | $760.27M | $796.23M |
| Return, 3 months | +47.6% | -22.1% |
| Return, year to date | +35.9% | -16.3% |
| Return, 1 year | +26.1% | +45.8% |
| P/E (TTM) | – | – |
| P/B | 1.9 | 4.3 |
| P/E percentile vs own 5y | 32nd | 33rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -48.5% | – |
| Net profit growth (YoY) | +22.5% | -12.6% |
| Gross margin | 68.0% | – |
| Operating margin | -228.6% | – |
| Net margin | -219.6% | – |
| Return on equity | -56.3% | -104.3% |
| Analyst target vs. price | -38.0% | +324.5% |
| Analyst buy share | 0% | 86% |
| RSI (14) | 52 | 55 |
| 30-day volatility | 157.2% | 76.8% |
| Max drawdown, 1 year | -59.1% | -51.0% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Sell | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ANNX is the largest of the group by market value.
- ANNX has returned the most over the past year.
- ANNX has been the calmest stock over the last 30 days.